Albireo Pharma Inc (ALBO) Cours

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome

Bylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille...

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases...

Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA

- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a low...

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases...

Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors

– Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise – Dr. Paul Streck, former Chief...

Albireo to Participate in Jefferies London Healthcare Conference

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...

Albireo Reports Q3 2022 Financial Results and Business Update

Bylvay® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 millionNew disease modification and native liver survival data with Bylvay in PFIC patients presented at...

Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types

Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modificationLong-term preservation of native liver in PFIC, improvements in pruritus, bile acids, and...

Albireo Announces 2022 SPARK Grant Winners

— Eight projects selected for inaugural year of the program — Projects provide solutions to make a tangible difference in the lives of PFIC patients BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE...